Circulating histocompatibility antigen (HLA) gene products may help differentiate benign from malignant indeterminate pulmonary lesions

Kanangat, Smriti; Seder, Christopher W.; Pergande, Melissa R; Lobato, Gabriela C.; Fhied, Cristina; Raouf, Maryam F.; Liptay, Michael J.; Borgia, Jeffrey A.

doi:10.1016/j.humimm.2018.04.003

Cited by 2 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MHC class II expression in peripheral blood was also analyzed in lung cancer patients 34,49–52. HLA-DR9 was found to have higher frequency in peripheral blood of lung cancer patients, while HLA-DR6 was found to have lower frequency in lung cancer patients than healthy controls by serological MHC typing 34.…”

Section: Mhc Class II Expression and Nsclcmentioning

confidence: 99%

“…Level of HLA-DQA1 28kDa band was significantly increased and HLA-DQA1 33-35kDa band was decreased in adenocarcinoma. These conclusions suggested that these molecules might be used for adenocarcinoma early diagnosis 52. However,the sample size of former research was not large and other pathological types of NSCLC should be included.…”

Section: Mhc Class II Expression and Nsclcmentioning

confidence: 99%

See 1 more Smart Citation

<p>Major histocompatibility complex class II molecule in non-small cell lung cancer diagnosis, prognosis and treatment</p>

Wang

Zhao

Zhang

et al. 2019

OTT

View full text Add to dashboard Cite

Lung cancer is one of the commonest cancers in the world. More than 70% of lung cancer patients are diagnosed with non-small cell lung cancer (NSCLC). Major histocompatibility complex class II (MHC class II), an important component in antigen presenting process, usually expresses on professional antigen presenting cells (APCs), and it can be induced by interferon-γ (IFN-γ). MHC class II can be expressed by NSCLC cells. In NSCLC patients, the expression of MHC class II can be correlated with the outcome of anti-programmed death-1 (anti-PD-1) therapy. This review summarizes MHC class II expression in NSCLC and the correlation between MHC class II and NSCLC diagnosis, prognosis and therapy.

show abstract

Section: Mhc Class II Expression and Nsclcmentioning

confidence: 99%

Section: Mhc Class II Expression and Nsclcmentioning

confidence: 99%

<p>Major histocompatibility complex class II molecule in non-small cell lung cancer diagnosis, prognosis and treatment</p>

Wang

Zhao

Zhang

et al. 2019

OTT

View full text Add to dashboard Cite

show abstract

“…The previous study has uncovered that NM reversed IFN-γ-induced up-regulation of PD-L1 in lung cancer and pancreatic cancer cells (Figure 2) (66). The pivotal immune escape factor human leukocyte antigen-ABC (HLA-ABC) may help differentiate benign from malignant indeterminate pulmonary lesions (67). The study of Homma et al was confirmed that NM influenced IFN-γ-induced HLA-ABC up-regulation in lung cancer and pancreatic cancer (11), suggesting that NM may improve the treatment of immune resistant cancer.…”

Section: Discussionmentioning

confidence: 99%

The Molecular Aspect of Antitumor Effects of Protease Inhibitor Nafamostat Mesylate and Its Role in Potential Clinical Applications

Chen

Zeng

et al. 2019

Front. Oncol.

View full text Add to dashboard Cite

Nafamostat mesylate (NM), a synthetic serine protease inhibitor first placed on the market by Japan Tobacco in 1986, has been approved to treat inflammatory-related diseases, such as pancreatitis. Recently, an increasing number of studies have highlighted the promising effects of NM in inhibiting cancer progression. Alone or in combination treatments, studies have shown that NM attenuates various malignant tumors, including pancreatic, colorectal, gastric, gallbladder, and hepatocellular cancers. In this review, based on several activating pathways, including the canonical Nuclear factor-κB (NF-κB) signaling pathway, tumor necrosis factor receptor-1 (TNFR1) signaling pathway, and tumorigenesis-related tryptase secreted by mast cells, we summarize the anticancer properties of NM in existing studies both in vitro and in vivo. In addition, the efficacy and side effects of NM in cancer patients are summarized in detail. To further clarify NM's antitumor activities, clinical trials devoted to validating the clinical applications and underlying mechanisms are needed in the future.

show abstract

Circulating histocompatibility antigen (HLA) gene products may help differentiate benign from malignant indeterminate pulmonary lesions

Abstract: Soluble HLA molecules may have diagnostic value for early-stage NSCLC. Validation studies are currently underway using sera from a lung cancer screening cohort.

Cited by 2 publications

References 20 publications

<p>Major histocompatibility complex class II molecule in non-small cell lung cancer diagnosis, prognosis and treatment</p>

<p>Major histocompatibility complex class II molecule in non-small cell lung cancer diagnosis, prognosis and treatment</p>

The Molecular Aspect of Antitumor Effects of Protease Inhibitor Nafamostat Mesylate and Its Role in Potential Clinical Applications

Contact Info

Product

Resources

About